Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Ke Xu, Weinan Lu, Airu Yu, Hongwei Wu, Jie He
BACKGROUND: This study aimed to systematically analyze the effect of a serine/threonine kinase (STK11) mutation (STK11mut ) on therapeutic efficacy and prognosis in patients with non-small cell lung cancer (NSCLC). METHODS: Candidate articles were identified through a search of relevant literature published on or before April 1, 2023, in PubMed, Embase, Cochrane Library, CNKI and Wanfang databases. The extracted and analyzed data included the hazard ratios (HRs) of PFS and OS, the objective response rate (ORR) of immune checkpoint inhibitors (ICIs), and the positive rates of PD-L1 expression...
April 17, 2024: BMC Cancer
#2
JOURNAL ARTICLE
Yanhua Wang, Jingwen Wei, Manyi Xu, Jing Xiang, Keda Shao, Yue Hao, Zhengbo Song
BACKGROUND: Mesenchymal epithelial transition factor (MET) is a rare oncologic driver gene, and information on immunotherapy for non-small cell lung cancer (NSCLC) patients with this driver gene is limited. Here we evaluate the efficacy and safety of immune checkpoint inhibitors (ICI) under different therapeutic regimen for NSCLC patients with MET alterations. METHODS: From June 2019 to December 2023, we assessed the efficacy and toxicity of ICIs in 42 NSCLC patients with MET alterations...
April 16, 2024: Clinical & Translational Oncology
#3
JOURNAL ARTICLE
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Nina Wyss, Fiamma Berner, Vincent Walter, Ann-Kristin Jochum, Mette T Purde, Marie-Therese Abdou, Tobias Sinnberg, Kathrin Hofmeister, Oltin T Pop, Omar Hasan Ali, Jens Bauer, Hung-Wei Cheng, Mechthild Lütge, Niklas Klümper, Stefan Diem, Zeynep Kosaloglu-Yalcin, Yizheng Zhang, Laura Sellmer, Boris Macek, Julia Karbach, David König, Heinz Läubli, Lars Zender, Britta S Meyer, Christoph Driessen, Christian M Schürch, Wolfram Jochum, Teresa Amaral, Lucie Heinzerling, Antonio Cozzio, Ahmed N Hegazy, Tino Schneider, Martin H Brutsche, Alessandro Sette, Tobias L Lenz, Juliane Walz, Hans-Georg Rammensee, Martin Früh, Elke Jäger, Burkhard Becher, Amanda Tufman, Nicolas Nuñez, Markus Joerger, Lukas Flatz
RATIONALE: Immune checkpoint inhibitor-related pneumonitis is a serious autoimmune event affecting up to 20% of patients with non-small cell lung cancer, yet the factors underpinning its development in some patients and not others are poorly understood. OBJECTIVES: To investigate the role of autoantibodies and autoreactive T cells against surfactant-related proteins in the development of pneumonitis. METHODS: The study cohort consisted of non-small cell lung cancer patients who gave blood samples before and during immune checkpoint inhibitor treatment...
April 16, 2024: American Journal of Respiratory and Critical Care Medicine
#4
JOURNAL ARTICLE
Giuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, Emilio Francesco Giunta, Akash Maniam, Shobana Anpalakhan, Shyamika Acharige, Aruni Ghose, Alfredo Addeo
IMPORTANCE: Randomized clinical trials (RCTs) with neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non-small cell lung cancer (NSCLC) have reported consistent associations with event-free survival (EFS) and pathologic complete response (pCR) pending longer follow-up for overall survival data. OBJECTIVE: To assess the pooled benefit of ICI-chemotherapy in 2-year EFS and pCR among patients with NSCLC and examine the impact of clinical, pathologic, and treatment-related factors...
April 1, 2024: JAMA Network Open
#5
JOURNAL ARTICLE
Chuang Yang, Tiantian Xuan, Qing Gong, Xin Dai, Chengjun Wang, Rongyu Zhang, Wen Zhao, Jian Wang, Weiming Yue, Jisheng Li
BACKGROUND: Patients with extensive-stage small cell lung cancer (ES-SCLC) have an exceptionally poor prognosis and immune checkpoint inhibitors (ICIs) combined with etoposide-platinum is recommended as standard first-line therapy. However, which combination pattern is the best still remains unknown. This network meta-analysis was performed to compare the efficacy and safety of currently available patterns including an antiangiogenic agent containing regimen and probed into the most appropriate therapy for patients...
April 16, 2024: Thoracic Cancer
#6
JOURNAL ARTICLE
Ken Yamamoto, Taira Ninomaru, Hideaki Okada, Katsuya Hirano, Temiko Shimada, Akito Hata
In non-small-cell lung cancer, continuous immune-checkpoint inhibitors (ICIs) beyond progression are often used in clinical practice. On the other hand, there is almost no data on whether the concept of continuous ICIs beyond progression can be adopted in small-cell lung cancer (SCLC). We describe the effectiveness of continuous ICIs beyond progression in SCLC. Medical courses of SCLC patients treated with chemo-immunotherapy were retrospectively reviewed at our hospital. The study included 36 patients with a median age of 73 years (range 46-83 years) who introduced chemo-immunotherapy between September 2019 and December 2022...
April 16, 2024: Thoracic Cancer
#7
Doah Kim, Jeong Kyeong Jang, Youngje Sung
INTRODUCTION: Given the recent additions of immune checkpoint inhibitors (ICIs) to various cancer treatments, adverse effects, especially involving the eyes, have been on the rise. Here, we report an acute exacerbation of cancer-associated retinopathy (CAR) triggered by durvalumab treatment of small-cell lung cancer (SCLC). CASE PRESENTATION: An 81-year-old Asian male complained of a scotoma in the left eye after durvalumab administration, to treat SCLC. Humphrey visual field examination revealed a C-shaped temporal scotoma...
2024: Case Reports in Ophthalmology
#8
JOURNAL ARTICLE
Jun Yamada, Takafumi Fukui, Atsuhiko Yatani, Chihiro Mimura, Kiyoko Fukuda, Daisuke Hazama, Naoko Katsurada, Tatsuya Nagano, Masatsugu Yamamoto, Motoko Tachihara
BACKGROUND: There have been reports on the impact of concurrent drugs on the outcome of immunotherapy for non-small cell lung carcinoma (NSCLC). However, the effect of some drugs, such as antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), has not been clarified in patients with NSCLC. In the present study, we aimed to assess the association between concurrent drugs and the outcomes of immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy for patients with advanced NSCLC...
April 15, 2024: Thoracic Cancer
#9
JOURNAL ARTICLE
Sunyin Rao, Li Min, Jie Zhao, Juan Su, Lianhua Ye
Chemoradiotherapy (CRT) followed by consolidation of immune checkpoint inhibitors (ICIs), such as durvalumab or pembrolizumab, for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) with tumor PD-L1 expression <1% remains a topic of controversy. Previous studies from PubMed, Cochrane Library and Embase databases were searched for a meta-analysis. A total of 16 studies were included in part one of the meta-analysis and it was observed that consolidation of ICIs after CRT improved overall survival (OS) [hazard ratio (HR) 1...
June 2024: Oncology Letters
#10
JOURNAL ARTICLE
Xiaoya Xu, Xiangru Shi, Dingjie Zhou, Dedong Cao
OBJECTIVE: This study aimed to assess the clinical value of the modified albumin-bilirubin (mALBI) grade in predicting the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy. METHODS: We conducted a retrospective cohort study of patients with advanced NSCLC who received immune checkpoint inhibitors (ICIs) from January 2020 to May 2022. The primary endpoints were overall survival (OS), treatment response, and the association between different mALBI grades and survival...
March 2024: Curēus
#11
JOURNAL ARTICLE
Yohei Kawaguchi, Nanako Nishioka, Taiyo Nakamura, Kentaro Imai, Takuya Aoki, Naohiro Kajiwara, Norihiko Ikeda
BACKGROUND: The effect of lymph node dissection (LND) on the efficacy of immune checkpoint inhibitor (ICI) remains unclear. The purpose of this study was to examine the difference in the effect of ICI between patients with non-small cell lung cancer (NSCLC) according to the extent of LND performed in surgery prior to postoperative recurrence. METHODS: A total of 134 patients with postoperative recurrence (surgery group, n=26) or unresectable advanced lung cancer (non-surgery group, n=108) who were treated with ICIs between January 2016 and December 2022 were included for analysis...
March 29, 2024: Journal of Thoracic Disease
#12
JOURNAL ARTICLE
Xiaoqi Yan, Luqing Zhao, Fei Wu, Bo Shen, Guoren Zhou, Jifeng Feng, Chao Yue, Jingni Zhu, Shaorong Yu
BACKGROUND: Immune checkpoint inhibitors (ICIs) have dramatically changed the first-line treatment pattern of non-small cell lung cancer (NSCLC) without driver gene alterations. However, the optimal choice for second-line treatment after initial treatment with ICIs is unclear. This study aimed to clarify the efficacy and safety of ICI rechallenge therapy in locally advanced and advanced NSCLC. METHODS: We retrospectively analyzed the histories of 224 patients with locally advanced or advanced NSCLC treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors alone or in combination with chemotherapy and/or antiangiogenic therapy in first-line treatment...
March 29, 2024: Journal of Thoracic Disease
#13
JOURNAL ARTICLE
Manyi Xu, Lan Xu, Yue Hao, Keda Shao, Zhengbo Song
BACKGROUND: With the widespread use of immune checkpoint inhibitors (ICIs), patients inevitably experience immune-related adverse events (irAEs). Therefore, the study was conducted on the clinical characteristics and outcomes of patients with non-small cell lung cancer (NSCLC) with immune-related hepatitis (ir-hepatitis). METHODS: We identified patients with advanced NSCLC who developed ir-hepatitis after immunotherapy between June 2016 and December 2022. Their irAEs were categorized according to the Common Terminology Criteria for Adverse Events version 4...
March 29, 2024: Journal of Thoracic Disease
#14
JOURNAL ARTICLE
Litang Huang, Shen Chen, Hui Liu, Lu Meng, Chengxing Liu, Xiaoting Wu, Yingying Wang, Shilan Luo, Hongbin Tu, Chunlei Wang, Ming Zhang, Xiaomei Gong
BACKGROUND: Numerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC-BMs). METHODS: We conducted a retrospective study by analyzing medical records of patients with SCLC-BMs from January 1, 2017 to June 1, 2022. Data related to median overall survival (mOS), median progression-free survival (mPFS), and intracranial progression-free survival (iPFS) were analyzed...
April 2024: Cancer Medicine
#15
REVIEW
Saurav Verma, Daniel Breadner, Abhenil Mittal, David A Palma, Rahul Nayak, Jacques Raphael, Mark Vincent
Immune-checkpoint inhibitors (ICIs) have an established role in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC). ICIs have now entered the paradigm of early-stage NSCLC. The recent evidence shows that the addition of ICI to neoadjuvant chemotherapy improves the pathological complete response (pCR) rate and survival rate in early-stage resectable NSCLC and is now a standard of care option in this setting. In this regard, stage III NSCLC merits special consideration, as it is heterogenous and requires a multidisciplinary approach to management...
March 27, 2024: Cancers
#16
JOURNAL ARTICLE
Wen Sun, Yuan Cheng, Xiaoyu Ma, Zhou Jin, Qi Zhang, Guangfa Wang
BACKGROUND: Photodynamic therapy (PDT) is a promising interventional treatment approach that contributes to antitumor immunity. It has been reported that PDT can enhance the effectiveness of immune checkpoint inhibitors (ICIs), but its mechanism is yet unclear. Herein, we implemented bioinformatics analysis to detect common pathways and potential biomarkers in non-small cell lung cancer (NSCLC), PDT, and NSCLC immunotherapy to investigate potential links between PDT, immunotherapy and NSCLC, and their clinical impact...
April 12, 2024: European Journal of Medical Research
#17
JOURNAL ARTICLE
Yijiao Xu, Qingwei Zhang, Zhisheng Chen, Shuwen Yang, Haiyan Chen, Xiong Xiao, Hongni Jiang
BACKGROUND: Tuberculosis (TB), a highly contagious respiratory disease, presents a significant global health threat, with a notable increase in incidence reported by the WHO in 2022. Particularly, the interplay between TB and non-small cell lung cancer (NSCLC) gains attention, especially considering the rising use of immune checkpoint inhibitors (ICIs) in cancer treatment. This interplay may influence TB diagnostics and reactivation, warranting a closer examination. METHODS: A retrospective analysis was conducted on clinical data of NSCLC patients with positive T-SPOT results before undergoing anti-tumor treatment at Zhongshan Hospital (Xiamen), Fudan University, from January 1, 2021 to December 31, 2022...
April 12, 2024: BMC Pulmonary Medicine
#18
Raluca Lazar, Cathie Fischbach, Roland Schott, Laura Somme
Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of cases of lung cancer. The standard first-line therapy for patients without oncogenic driver metastatic NSCLC is anti PD-L1 immune checkpoint inhibition (ICI) with platinum-based chemotherapy. Approximately 4% of NSCLC patients harbor BRAF mutations; the V600E mutation is the most common. Non-V600 mutations is an heterogeneous population and account for approximately 50% of BRAF -mutated NSCLC. BRAF mutations are classified into 3 functional classes based on their kinase activity and their signaling mechanism...
2024: Frontiers in Oncology
#19
JOURNAL ARTICLE
Jingyuan Xie, Ke Xu, Zijing Cai, Mo Chen, Yuxin Jiang, Jinjun Ye, Xinqing Lin, Tangfeng Lv, Ping Zhan
BACKGROUND: The prognosis of small cell lung cancer (SCLC) patients is poor, and the standard first-line treatment for limited-stage small cell lung cancer (LS-SCLC) is still chemotherapy and thoracic radiotherapy. The primary objectives of our study were to confirm the superior efficacy of first-line immune checkpoint inhibitors (ICIs) plus etoposide and platinum (EP) for LS-SCLC and find crucial biomarkers. METHODS: We analyzed LS-SCLC patients from three medical centers, employing propensity score matching for group comparability...
March 29, 2024: Translational Lung Cancer Research
#20
JOURNAL ARTICLE
Eyal Tsur, Philip Blumenfeld, Yakir Rottenberg, Hovav Nechushtan, Johnathan Arnon, Ori Wald, Uzi Izhar, Raphael Pfeffer, Aron Krakow, Marc Wygoda, Aron Popovtzer, Tal Falick Michaeli
BACKGROUND: Stereotactic body radiation therapy (SBRT) is often delivered in patients with oligometastatic disease (OMD). However, the specific subset of patients with polymetastatic non-small cell lung cancer (NSCLC) on novel systemic therapies who develop induced oligopersistant disease (OpersisD) or oligoprogressive disease (OprogD), as defined by the European Organisation for Research and Treatment of Cancer (EORTC) OMD classification, has not been well described. This study explores the outcomes of patients treated with this strategy...
March 29, 2024: Translational Lung Cancer Research
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
